Ionis Pharmaceuticals, Inc. Tax Withholding Paid on Stock Awards
Ionis Pharmaceuticals, Inc. (IONS) reported Tax Withholding Paid on Stock Awards of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2025-02-19
- Ionis Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Ionis Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Ionis Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Ionis Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Ionis Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $0.00.
- Ionis Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Ionis Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $10.95M, a 34.51% decline from fiscal 2021.
- Ionis Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2021 was $16.73M, a 24.71% increase from fiscal 2020.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-19 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $0.00 derived: sum of 2 quarters · filed 2025-02-19 | $0.00 derived: sum of 3 quarters · filed 2025-02-19 | $0.00 10-K · filed 2025-02-19 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | $736.00K derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | $736.00K derived: sum of 3 quarters · filed 2025-02-19 | $1.38M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-03 | $736.00K derived: sum of 2 quarters · filed 2025-02-19 | $1.38M derived: sum of 3 quarters · filed 2025-02-19 | $1.78M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $736.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $1.38M derived: sum of 2 quarters · filed 2025-02-19 | $1.78M derived: sum of 3 quarters · filed 2025-02-19 | $10.95M 10-K · filed 2025-02-19 |
| 2022-09-30 | $645.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.04M derived: sum of 2 quarters · filed 2023-11-02 | $10.22M 10-Q · filed 2023-11-02 | $10.66M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $399.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $9.57M 10-Q · filed 2023-08-09 | $10.01M derived: sum of 3 quarters · filed 2024-02-21 | $10.50M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $9.17M 10-Q · filed 2023-05-03 | $9.61M derived: sum of 2 quarters · filed 2024-02-21 | $10.10M derived: sum of 3 quarters · filed 2024-02-21 | $10.56M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $440.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $930.00K derived: sum of 2 quarters · filed 2024-02-21 | $1.39M derived: sum of 3 quarters · filed 2024-02-21 | $16.73M 10-K · filed 2024-02-21 |
| 2021-09-30 | $490.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $948.00K derived: sum of 2 quarters · filed 2022-11-09 | $16.29M 10-Q · filed 2022-11-09 | $16.74M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $458.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $15.79M 10-Q · filed 2022-08-09 | $16.25M derived: sum of 3 quarters · filed 2023-02-22 | $17.23M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $15.34M 10-Q · filed 2022-05-04 | $15.79M derived: sum of 2 quarters · filed 2023-02-22 | $16.78M derived: sum of 3 quarters · filed 2023-02-22 | $17.14M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $451.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $1.44M derived: sum of 2 quarters · filed 2023-02-22 | $1.81M derived: sum of 3 quarters · filed 2023-02-22 | $13.41M 10-K · filed 2023-02-22 |
| 2020-09-30 | $989.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $1.36M derived: sum of 2 quarters · filed 2021-11-03 | $12.96M 10-Q · filed 2021-11-03 | $13.36M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $368.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $11.97M 10-Q · filed 2021-08-04 | $12.37M derived: sum of 3 quarters · filed 2022-02-25 | $23.18M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $11.60M 10-Q · filed 2021-05-05 | $12.00M derived: sum of 2 quarters · filed 2022-02-25 | $22.81M derived: sum of 3 quarters · filed 2022-02-25 | $23.25M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $401.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $11.21M derived: sum of 2 quarters · filed 2022-02-25 | $11.64M derived: sum of 3 quarters · filed 2022-02-25 | $19.24M 10-K · filed 2022-02-25 |
| 2019-09-30 | $10.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $11.24M derived: sum of 2 quarters · filed 2020-11-04 | $18.84M 10-Q · filed 2020-11-04 | $18.84M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $437.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $8.03M 10-Q · filed 2020-08-05 | $8.03M derived: sum of 3 quarters · filed 2021-02-24 | $8.03M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $7.60M 10-Q · filed 2020-05-06 | $7.60M derived: sum of 2 quarters · filed 2021-02-24 | $7.60M derived: sum of 3 quarters · filed 2021-02-24 | $7.60M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $0.00 derived: sum of 2 quarters · filed 2021-02-24 | $0.00 derived: sum of 3 quarters · filed 2021-02-24 | $0.00 10-K · filed 2021-02-24 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $0.00 derived: sum of 2 quarters · filed 2019-11-06 | $0.00 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |